Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

May 2024

The association between genetics and response to treatment with biologics in patients with psoriasis, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases: A systematic review and meta-analysis

Journal Reference: Int J Mol Sci 2024;25:5793 doi: 10.3390/ijms25115793

Skov L,

Genetic variants in TNFα, NLRP3, MYD88, and FcRγ genes were associated with a response to TNFi, when assessing several inflammatory diseases together. Al-Sofi et al. conducted a systematic review and meta-analysis on single nucleotide polymorphism (SNP) genetic markers and their response to biologics in psoriasis, PsA, RA, IBD, and across all chronic inflammatory diseases together.

Keywords:

October 2023

Risque d'événements cardiovasculaires majeurs dans les troubles inflammatoires à médiation immunitaire sous l'effet de produits biologiques et de petites molécules : Méta-analyse en réseau

CClin Gastroenterol Hepatol 2023;22:961-970.e12

Yarur A,

Singh S,

Deepak P

The results of this study show that anti-IL-12/23, JAK inhibitors, and anti-TNF-α were associated with slightly higher risk of MACE compared with placebo. The risk was no different between biologic treatments, and the magnitude of risk did not differ between IMID type.

Keywords:

Traitement au bimékizumab chez les patients atteints de spondylarthrite axiale active: efficacité et innocuité à 52 semaines des études randomisées et parallèles de phase 3 BE MOBILE 1 et BE MOBILE 2

Ann Rheum Dis. 2023;83(2):199–213 doi 10.1136/ard-2023-224803

Xu H,

Vaux T,

Baraliakos, et al. present data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, that investigated the clinical efficacy and safety of bimekizumab in axSpA patients. They found that bimekizumab had sustained and consistent efficacy in patients with nr-axSpA and r-axSpA.

Keywords:

April 2023

Factors Associated with the Retention of Secukinumab in Patients with Axial Spondyloarthritis in Real-world Practice: Results from a Retrospective Study (FORSYA)

RMD Open 2023;9:e002802 doi: 10.1136/rmdopen-2022-002802

Lucas J,

This study reported the overall retention of secukinumab in daily practice in the period following its approval in France was approximately 59% at 1 year in axSpA patients. The aim of this study was to determine whether OSI were predictive of secukinumab retention at 1 year.

Keywords:

October 2022

Signaux de toxicité associés au sécukinumab : Une étude de pharmacovigilance basée sur la base de données du système de notification des effets indésirables de la Food And Drug Administration des États-Unis

Br J Clin Pharmacol. 2022 doi: 10.1111/bcp.15535

Zheng Y,

Guo X,

Chen C,

Chi L,

Guo Z,

Liang J,

Wei L,

Chen X,

Ye X,

He J

This study explored the clinical characteristics, outcomes, and time to onset of the four main toxicities of secukinumab with hypersensitivity identified as the most common toxicity.

Keywords:

May 2022

Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: Results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal Phase 3 FORTIFY maintenance trial

Lancet 2022;399:2031–36 doi: 10.1016/S0140-6736(22)00466-4

Baert F,

Lim A,

Ran Z,

Song A,

Pang Y,

Berg S,

Duan WR,

Huang B,

Liao X,

Maintenance treatment with risankizumab was associated with an improvement in coprimary endpoints of clinical remission and endoscopic response in patients with Crohn’s disease compared with placebo.

Keywords:

Traitement de la spondyloarthrite axiale : une mise à jour

Nat Rev Rheumatol. 18, 205–216 (2022) 2022 doi: 10.1038/s41584-022-00761-z

Danve A & Deodhar A

In this review Danve and Deodhar report an update on modern axSpa treatment. They found that in the past two decades substantial progress in the diagnosis and management of axSpA has been witnessed. Whilst ASAS classification criteria have enabled earlier diagnosis the increased availability of novel therapies, evolving drug safety data and novel clinical trials have allowed clinicians to rethink the placement and timing of drugs in disease management.

Keywords:

Review

December 2020

Points À Considérer Pour le Traitement des Maladies Inflammatoires Immunitaires par les Inhibiteurs de Janus Kinase : une Recherche Bibliographique Systématique

RMD Open 2020;6:e001374 doi:10.1136/rmdopen-2020-001374

Nash P,

Trials of JAKi have been conducted in many therapy areas, including rheumatology, dermatology and gastroenterology. In 2019, a task force was set up to create a consensus to guide clinicians on how to use JAKi in clinical practice. This systematic literature review conducted in 2019 support this consensusIn line with EULAR’s standardised operating procedures for recommendations, a literature search was conducted in EMBASE, Medline and the Cochrane Library databases. To evaluate the efficacy of t...

Keywords:

JAK,
Review

October 2013

Involvement of JAK/STAT signalling in the pathogenesis of inflammatory bowel disease

Pharmacological Research 2013; 76:1–8

Coskun M,

Salem M,

Pedersen J,

Nielsen OF

The JAK/STAT signalling pathway has been implicated in the pathogenesis of several inflammatory diseases including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). In this review, Coskun et al. provide an excellent background overview of the JAK/STAT cascade. They also highlight recent study findings investigating the mechanisms of the JAK/STAT pathway and the anti-inflammatory effects of novel JAK inhibitors in development and in clinical trials, particularly in IBD. In one study...